AFT — AFT Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- NZ$482.38m
- NZ$525.04m
- NZ$254.71m
Brief: AFT Pharmaceuticals Signs New Licence Agreements For Maxigesic Pain Relief Medicine
NZ's AFT Pharmaceuticals set for best day in 7 months on FDA nod for tablet launch
Brief: Aft Pharmaceuticals Says US FDA Approved Rapid Release Tablet Form Of Maxigesic
Brief: AFT Pharmaceuticals To Develop Antibiotic Eye Drop
Brief: AFT Pharmaceuticals Says It Signed Exclusive Licensing And Distribution Agreement
NZ's AFT Pharmaceuticals slumps on dismal HY results
Brief: AFT Pharmaceuticals Says Half-Year Operating Revenue Up 18.4%
Brief: AFT Pharmaceuticals Updates On Programme To Obtain U.S. FDA Registration Of Maxigesic IV
Brief: Aft Pharmaceuticals Says Co Has Reached Agreement With Massey Ventures And Gillies Mcindoe Research Institute
Brief: AFT Pharmaceuticals Says Co And Roolife Launch OTC Medicines Online In China
AFT Pharmaceuticals eyes best day in 6-weeks on launching OTC meds in China
NZ's AFT Pharmaceuticals hits over 3-week high on upbeat annual results
Brief: AFT Pharmaceuticals Says Annual Operating Revenue Up 15.2% To NZ$130.3 Million
Brief: Aft Pharmaceuticals Welcomes Dismissal Of Application By Reckitt & Benckiser To Appeal Comparative Advertising Judgement Handed Down In Dec 2021
Brief: AFT Pharmaceuticals Notes U.S. FDA Approval For Pascomer Alternative By Japan's Nobelpharma
Australia Stock Exchange release from AFT PHARMACEUTIC : FFC: Farmaforce and AFT Pharmaceuticals Partnership
Australia Stock Exchange release from AFT PHARMACEUTIC : Disclosure of Directors & Senior Managers Relevant Interests
NZ's AFT Pharma jumps on retaining earnings outlook for FY22
Australia Stock Exchange release from AFT PHARMACEUTIC : 2022 New Year letter to investors